These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9647613)

  • 1. Ongoing and unsaid on oxaliplatin: the hope.
    Cvitkovic E
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):8-11. PubMed ID: 9647613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oxaliplatin: the first DACH platinum in clinical practice].
    Soulié P; Raymond E; Brienza S; Cvitkovic E
    Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin: a review of preclinical and clinical studies.
    Raymond E; Chaney SG; Taamma A; Cvitkovic E
    Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin: mechanism of action and antineoplastic activity.
    Raymond E; Faivre S; Woynarowski JM; Chaney SG
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
    Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
    Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of oxaliplatin in the treatment of gastric cancer.
    Zaniboni A; Meriggi F
    J Chemother; 2005 Dec; 17(6):656-62. PubMed ID: 16433197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin clinical activity: a review.
    Misset JL; Bleiberg H; Sutherland W; Bekradda M; Cvitkovic E
    Crit Rev Oncol Hematol; 2000 Aug; 35(2):75-93. PubMed ID: 10936465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin in tumors other than colorectal cancer.
    Lorusso PM
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):33-7. PubMed ID: 11204661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and molecular aspects of drugs of the future: oxaliplatin.
    Di Francesco AM; Ruggiero A; Riccardi R
    Cell Mol Life Sci; 2002 Nov; 59(11):1914-27. PubMed ID: 12530522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oxaliplatin: a first DACH-platinum in oncology].
    Laadem A; Cvitkovic E
    Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin in practice.
    Misset JL
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of DNA mismatch repair in platinum drug resistance.
    Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
    Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
    Stordal B; Pavlakis N; Davey R
    Cancer Treat Rev; 2007 Jun; 33(4):347-57. PubMed ID: 17383100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of platinum compounds.
    Hartmann JT; Lipp HP
    Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.